ANTI-CD43 ANTIBODY AND USE THEREOF FOR CANCER TREATMENT

To provide compositions for inhibiting a cancer stem cell.SOLUTION: A pharmaceutical composition comprises an anti-CD43 antibody or an antigen-binding fragment thereof, the antibody or fragment comprising a CDR1H of SEQ ID NO: 111, a CDR2H of SEQ ID NO: 114, a CDR3H of SEQ ID NO: 118, a CDR1L of SEQ...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	IRENE KOUKOULAS, VINCENT BATORI, HONG KWON PYO, DAVID S WILSON JR, YOON SANGSOON, BRIONY CRISTIANO, GEORGE KOPSIDAS
Format:	Patent
Sprache:	eng ; jpn
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To provide compositions for inhibiting a cancer stem cell.SOLUTION: A pharmaceutical composition comprises an anti-CD43 antibody or an antigen-binding fragment thereof, the antibody or fragment comprising a CDR1H of SEQ ID NO: 111, a CDR2H of SEQ ID NO: 114, a CDR3H of SEQ ID NO: 118, a CDR1L of SEQ ID NO: 119, a CDR2L of SEQ ID NO: 124, and a CDR3L of SEQ ID NO: 125. Preferably, the antigenic site consists of an amino acid sequence selected from SEQ ID NOs: 131, 132, 133 and 134.SELECTED DRAWING: Figure 1 【課題】癌幹細胞阻害用組成物の提供。【解決手段】ＳＥＱＩＤＮＯ：１１１のＣＤＲ１Ｈ、ＳＥＱＩＤＮＯ：１１４のＣＤＲ２Ｈ、ＳＥＱＩＤＮＯ：１１８のＣＤＲ３Ｈ、ＳＥＱＩＤＮＯ：１１９のＣＤＲ１Ｌ、ＳＥＱＩＤＮＯ：１２４のＣＤＲ２Ｌ、及びＳＥＱＩＤＮＯ：１２５のＣＤＲ３Ｌを含む、抗ＣＤ４３抗体又はその抗原結合断片を含有する医薬組成物。好ましくは、抗原決定部位は、ＳＥＱＩＤＮＯ：１３１、１３２、１３３、及び１３４から選択されたアミノ酸配列からなる、医薬組成物。【選択図】図１